Mebastin (mebhydrolin)
/ Incepta Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
April 14, 2025
Pd/NBE-Catalyzed One-Pot Modular Synthesis of Tetrahydro-γ-carbolines.
(PubMed, J Org Chem)
- "Here, using commercially available NBE derivatives (NBEs), we report an efficient protocol for the one-pot modular synthesis of 4-substituted tetrahydro-γ-carbolines via Catellani/aza-Michael addition cascade from easily available 3-iodo-1-tosyl-1H-indole, aziridines and olefins. This approach exhibits a wide substrate scope, good yields, scalability, and potential extension toward the synthesis of Mebhydroline analogues."
Journal
July 29, 2022
Repurposing of the antihistamine mebhydrolin napadisylate for treatment of Zika virus infection.
(PubMed, Bioorg Chem)
- "Our data together suggest that MHL suppresses ZIKV infection through the inhibition of ZIKV NS5 RdRp activity. This study highlights that MHL might be a promising clinical anti-ZIKV therapeutic."
Journal • CNS Disorders • Infectious Disease
April 10, 2021
Antiallergic drug Mebhydrolin ameliorates glucose homeostasis in type 2 diabetic mice by functioning as a selective FXR antagonist.
(PubMed, Metabolism)
- "Our work has revealed a novel mode for the regulation of FXR against glucose metabolism in T2DM mice and highlighted the potential of Mebhydrolin in the treatment of T2DM."
Journal • Preclinical • Diabetes • Dyslipidemia • Metabolic Disorders • Type 2 Diabetes Mellitus • FOXO1 • GSK3B
1 to 3
Of
3
Go to page
1